Clinical MedicineUpdated Aug 6, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from Science Translational Medicine indicates that T cell-inflamed tumors express high levels of IDO, PD-L1, and FoxP3+ regulatory T cells. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied.
Evidence from Science Immunology indicates that Melanin in the patch generates heat upon near-infrared light irradiation. This is tracked as a breakthrough because it changes how Personalized cancer vaccines is understood, validated, or applied.
Evidence from Nature Communications indicates that PVAX inhibits tumor relapse by promoting dendritic cell maturation and eliciting cytotoxic T lymphocyte infiltration. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Frontiers in Immunology indicates that Structural modeling and energetic scoring can predict neoantigen immunogenicity. This is tracked as a method because it changes how Personalized cancer vaccines is understood, validated, or applied.